Unveiling hierarchy and spatial distribution of O6‐methylguanine‐DNA methyltransferase promoter methylation in World Health Organization grade 2–3 gliomas

Abstract

AbstractThis study investigated the role of O6‐methylguanine‐DNA methyltransferase promoter (MGMTp) methylation hierarchy and heterogeneity in grade 2–3 gliomas, focusing on variations in chemotherapy benefits and resection dependency. A cohort of 668 newly diagnosed grade 2–3 gliomas, with comprehensive clinical, radiological, and molecular data, formed the basis of this analysis. The extent of resection was categorized into gross total resection (GTR ≥100%), subtotal resection (STR >90%), and partial resection (PR ≤90%). MGMTp methylation levels were examined using quantitative pyrosequencing. Our findings highlighted the critical role of GTR in improving the prognosis for astrocytomas (IDH1/2‐mutant and 1p/19q non‐codeleted), contrasting with its lesser significance for oligodendrogliomas (IDH1/2 mutation and 1p/19q codeletion). Oligodendrogliomas demonstrated the highest average MGMTp methylation levels (median: 28%), with a predominant percentage of methylated cases (average methylation levels >20%). Astrocytomas were more common in the low‐methylated group (10%–20%), while IDH wild‐type gliomas were mostly unmethylated (<10%). Spatial distribution analysis revealed a decrement in frontal lobe involvement from methylated, low‐methylated to unmethylated cases (72.8%, 59.3%, and 47.8%, respectively). In contrast, low‐methylated and unmethylated cases were more likely to invade the temporal‐insular region (19.7%, 34.3%, and 40.4%, respectively). Astrocytomas with intermediate MGMTp methylation were notably associated with temporal‐insular involvement, potentially indicating a moderate response to temozolomide and underscoring the importance of aggressive resection strategies. In conclusion, our study elucidates the complex interplay of MGMTp methylation hierarchy and heterogeneity among grade 2–3 gliomas, providing insights into why astrocytomas and IDH wild‐type lower‐grade glioma might derive less benefit from chemotherapy.